Schizophrenia News

SAN ANTONIO — Approximately 80% of individuals involved in a patient information program were adherent to long-acting injectable paliperidone palmitate or risperidone medication, according to data presented at U.S. Psychiatric and Mental Health Congress.

Higher resting heart rate and blood pressure were associated with increased risk for obsessive-compulsive disorder, schizophrenia and anxiety disorders in Swedish men, according to recent findings.

SAN ANTONIO — As the legalization of cannabis increases across the U.S., clinicians should be prepared on how to manage patients who use cannabis, according to Andrew Penn, RN, MS, NP, APRN-BC, of Kaiser Permanente, Redwood City, California; and the University of California, San Francisco.

The U.S. Psychiatric & Mental Health Congress will begin Friday, October 21 and conclude Monday, October 24.

Recent findings indicated an increased risk for psychosis relapse among individuals with first-episode psychosis who continued to use cannabis.

The FDA recently approved a supplemental New Drug Application for changes to the product label and Risk Evaluation Mitigation Strategy Program for Adasuve, an inhalation powder for acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.

The European College of Neuropsychopharmacology Congress, which took place from September 17 to 20 in Vienna, featured presentations, posters, abstracts and addresses on a broad range of topics associated with psychiatry, neurology, psychology, pharmacology and pediatrics.

Results from a second phase 3 clinical trial indicated ITI-007, an oral investigational treatment for schizophrenia, was not superior to placebo, while the active control risperidone was superior, according to a press release from Intra-Cellular Therapies.

The FDA approved a labeling update to Rexulti to reflect findings from a longitudinal randomized withdrawal trial assessing maintenance treatment among adults with schizophrenia.

Individuals with a sibling with schizophrenia were approximately ten times more likely to develop the disorder and had increased risk for bipolar disorder and other mental health disorders, according to findings presented at the European College of Neuropsychopharmacology Congress.